| CTVA |
Report |
Operating EPS (Q2 2026) |
BEAT |
pred ~$2.36 vs. cons $2.249 |
MEDIUM |
| CTVA |
Report |
Operating EBITDA (Q2 2026) |
BEAT |
pred ~$2.33B vs. cons $2.223B |
MEDIUM |
| CTVA |
Report |
Total Revenue (Q2 2026) |
IN-LINE |
pred ~$6.65B vs. cons $6.589B |
MEDIUM |
| CTVA |
Guide |
FY 2026 Operating EPS (FY 2026) |
LOWER |
guide ~$3.575 midpoint vs. cons $3.781 |
HIGH |
| CTVA |
Guide |
FY 2026 Operating EBITDA (FY 2026) |
LOWER |
guide ~$4.1B midpoint vs. cons $4.203B |
HIGH |
| CTVA |
Guide |
Dis-synergy update (qualitative) |
BETTER |
formal number ~$60-75M net vs. $100M initial estimate |
MEDIUM |
| CTVA |
Guide |
CP Pricing tone (qualitative) |
UNCHANGED |
low single-digit negative maintained; cautious H2 optimism |
MEDIUM |
| CTVA |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
MEDIUM |
| CTVA |
Return |
5-day cumulative residual |
-3.5% (FADE) |
FADE — FY estimate revisions pull toward guide midpoint; all three comparable C-quarters showed negative 5d residuals averaging -3.0% |
MEDIUM |